What We’re Reading: Back to School, Circumcision and HIV, and ARVs in DRC
By Jane Coaston | September 6, 2013
This week, we’re taking a crash course in HIV and AIDS, thinking about how male circumcision could affect the fight to eliminate HIV, and learning about how health professionals are learning important lessons while working with the Elizabeth Glaser Pediatric AIDS Foundation.
EGPAF – “Back to School with the Elizabeth Glaser Pediatric AIDS Foundation Part 1 and 2” How did the Elizabeth Glaser Pediatric AIDS Foundation get its start? How do you explain HIV to children? What is HIV and why is it so deadly? Learn about HIV, AIDS, and what EGPAF is doing to create an AIDS-free generation.
Global Post – “Follow-up study backs circumcision against HIV” Male circumcision has been proven to be a potential tool in the battle to prevent HIV transmission. This week, another series of trials that took place in South Africa, Kenya, and Uganda showed that male circumcision can reduce the risk of HIV infection in men by up to 75 percent.
EGPAF – “Building the Next Generation of Health Professionals” We’re so proud to partner with the Global Health Corps to provide much-needed experience to young health professionals in our country offices. Meet our fourth class of GHC fellows!
IRIN – “ARV treatments in Congo stop as supply chain interrupted” Antiretroviral (ARV) drug treatments are critical for people living with HIV, but in Democratic Republic of the Congo, the supply chain that gets drugs to the people who need them has been “broken” according to a local non-governmental organization (NGO) focused on human rights. More than 35,000 people are waiting for ARVs in Congo.
Huffington Post – “HIV Vaccine: Western University Researchers Report Success In Trials” A vaccine, made from a “dead” version of HIV, has passed the first round of clinical trials according to the Schulich School of Medicine & Dentistry at Western University. The researchers involved in the study believe that if the trials continue to be successful, a version of the vaccine could be commercially available within five years.
Jane Coaston is Media Relations Coordinator for the Foundation, based in Washington, D.C.